Real-world efficacy of cabozantinib alone or in combination with ICIs in heavily pretreated hepatocellular carcinoma: potential role of AXL and MET expression
This study highlights the potential of cabozantinib combined with immunotherapy in heavily pretreated HCC, with AXL expression as a possible predictive biomarker.
Authors
- Te-Lin Hsu (ORCID: https://orcid.org/0000-0002-3572-2340)
- Yee Chao (ORCID: https://orcid.org/0000-0001-5578-340X)
- San‐Chi Chen (ORCID: https://orcid.org/0000-0002-9436-5400)
- Shih-Yao Lin (ORCID: https://orcid.org/0000-0002-4364-0505)
- Nai‐Jung Chiang (ORCID: https://orcid.org/0000-0003-2743-9702)
- Kuan-Chang Lai
- Ming Huang Chen
- Muh-Hwa Yang
Institutions
- National Yang Ming Chiao Tung University (TW)
- Taipei Veterans General Hospital (TW)
- Central Clinical Hospital (PL)
Publication Details
- Journal
- Annals of Hepatology
- Published
- 2025-04-24
- DOI
- https://doi.org/10.1016/j.aohep.2025.101917
- Citations
- 3
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 3.14